Welcome to our dedicated page for Regulus Therapeu news (Ticker: RGLS), a resource for investors and traders seeking the latest updates and insights on Regulus Therapeu stock.
Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical innovator focused on developing microRNA-targeted therapies through advanced oligonucleotide technology. This page serves as the definitive source for official company announcements, research milestones, and regulatory developments.
Investors and researchers will find timely updates on clinical trial progress, including the Phase 1b study of RGLS8429 for autosomal dominant polycystic kidney disease (ADPKD). Our curated news collection provides essential insights into therapeutic advancements, partnership agreements, and strategic initiatives shaping the company's trajectory.
The repository features rigorously verified information across key categories: clinical program updates, financial disclosures, intellectual property developments, and scientific publications. Each entry maintains factual accuracy while highlighting implications for Regulus' position in the precision medicine landscape.
Bookmark this page for direct access to primary source materials from Regulus Therapeutics. Regularly updated content ensures stakeholders maintain current understanding of the company's progress in addressing complex diseases through RNA-targeted therapeutics.
Regulus Therapeutics (Nasdaq: RGLS) presented at the first annual Rare & Genetic Kidney Disease Drug Development Summit, highlighting its research on microRNAs (miRs) for treating genetic kidney diseases. The Company reported a 58% and 38% increase in biomarkers PC1 and PC2 in ADPKD patients following treatment with its drug RGLS4326. Regulus is prioritizing its second-generation miR-17 inhibitor RGLS8429, with a pre-IND meeting scheduled with the FDA in December 2021, aiming for IND submission by Q2 2022.
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced the successful completion of a private equity placement, raising approximately $34.6 million. This was achieved by selling about 58.9 million shares of common stock at $0.36 per share and 3.7 million shares of non-voting convertible preferred stock at $3.60 per share. The proceeds will support non-clinical and clinical development activities. The financing was facilitated by SVB Leerink as the lead placement agent and H.C. Wainwright as co-placement agent.
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced a private placement financing led by Federated Hermes Kaufmann Funds and New Enterprise Associates, aiming to raise approximately $34.6 million. This financing involves the purchase of about 58.9 million shares of common stock at $0.36 per share and 3.7 million shares of non-voting Class A-4 convertible preferred stock at $3.60 per share, convertible into common stock. The closing is expected around November 30, 2021, pending customary conditions.
Regulus Therapeutics (Nasdaq: RGLS) reported its Q3 2021 financial results on November 10, 2021. The company had $35.8 million in cash as of September 30, 2021, with net losses of $8.6 million for the quarter. Regulus is focusing on the development of RGLS8429 for ADPKD, having discontinued RGLS4326 due to its limitations. A pre-IND meeting with the FDA is expected in December 2021, with clinical development anticipated in Q2 2022. The company reported increased R&D expenses of $5.9 million for the quarter, up from $4.0 million the previous year.
Regulus Therapeutics Inc. (RGLS) announced it will report its financial results for Q3 2021 on November 10, 2021, after market close. A conference call and webcast will also be held on the same day at 5:00 PM EDT. The call can be accessed domestically at (877) 257-8599 or internationally at (970) 315-0459, with a replay option available. The company focuses on microRNA-targeted medicines and notes potential risks affecting its business, including impacts from the COVID-19 pandemic.
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced a strategic focus on RGLS8429 for treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). Following the completion of IND-enabling toxicity studies, the firm plans to submit an Investigational New Drug (IND) application and has scheduled a Phase 1 study in Q2 2022, subject to FDA approval. The decision stems from recent data suggesting RGLS8429's improved pharmacological profile and absence of negative CNS effects previously seen with RGLS4326. Initial biomarker data is expected in early 2023.
Regulus Therapeutics (Nasdaq: RGLS) announced that its director, David Baltimore, Ph.D., received the 2021 Lasker-Koshland Special Achievement Award for his significant contributions to virology, immunology, and cancer. This prestigious award celebrates advances in medical science and highlights the importance of public support for research. The CEO, Jay Hagan, praised Dr. Baltimore's extensive work and its influence on biotechnology and public health, including his role during the AIDS crisis. Regulus continues to benefit from his guidance in advancing its pipeline of microRNA therapeutics.
Regulus Therapeutics (Nasdaq: RGLS), a biopharmaceutical company specializing in microRNA therapeutics, announced that its CEO, Jay Hagan, will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. ET. The presentation will be accessible via an on-demand webcast available on their investor relations website. A replay will be archived for 30 days. Regulus focuses on developing innovative medicines and holds a strong intellectual property portfolio in the microRNA sector.
Regulus Therapeutics (Nasdaq: RGLS) reported its Q2 2021 financial results and key program developments, emphasizing progress in its ADPKD treatment program. Notably, the second cohort in the Phase 1b trial of RGLS4326 has been enrolled, with topline data expected soon. Financially, Regulus raised $15.4 million through an ATM facility and had $41.4 million in cash as of June 30, 2021. The net loss was $6.0 million for the quarter, improving from $6.9 million in the previous year. The company plans to discuss remaining clinical hold requirements with the FDA.
Regulus Therapeutics (Nasdaq: RGLS) will announce its financial results for Q2 2021 on August 10, 2021, after market close. The company will host a conference call at 5:00 PM ET on the same day to discuss the results and provide corporate updates. CEO Jay Hagan will also speak at the Wedbush PacGrow Healthcare Conference on August 11, 2021. Regulus focuses on developing innovative medicines targeting microRNAs and emphasizes its drug discovery expertise and intellectual property in this field. The release mentions forward-looking statements subject to various risks and uncertainties.
